Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DFF003
MIFTS: 44

Diffuse Scleroderma

Categories: Skin diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diffuse Scleroderma

About this section

MalaCards integrated aliases for Diffuse Scleroderma:

Name: Diffuse Scleroderma 12 14 69
Systemic Sclerosis, Diffuse 12
Diffuse Systemic Sclerosis 12
Systemic Scleroderma 69
Scleroderma, Diffuse 41

Classifications:

MalaCards categories:
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1580
MeSH 41 D045743
NCIt 46 C116791
SNOMED-CT 64 128460000 444133002
UMLS 69 C1258104
Sources

Summaries for Diffuse Scleroderma

About this section
MalaCards based summary : Diffuse Scleroderma, also known as systemic sclerosis, diffuse, is related to systemic scleroderma and scleroderma, familial progressive, and has symptoms including hidebound skin, pruritus and exanthema. An important gene associated with Diffuse Scleroderma is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are NF-kappaB Signaling and Apoptosis and Autophagy. The drugs Bosentan and Silver sulfadiazine have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and endothelial.

Sources

Related Diseases for Diffuse Scleroderma

About this section

Diseases related to Diffuse Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
# Related Disease Score Top Affiliating Genes
1 systemic scleroderma 32.4 EDN1 TGFB1 TOP1
2 scleroderma, familial progressive 32.3 EDN1 TOP1
3 limited scleroderma 29.1 MNDA PYHIN1 TOP1
4 collagen disease 28.7 EDN1 TOP1 TRIM21
5 diffuse cutaneous systemic sclerosis 11.1
6 reynolds syndrome 11.0
7 malignant secondary hypertension 10.2 EDN1 KNG1
8 eisenmenger syndrome 10.2 EDN1 TGFB1
9 coronary artery vasospasm 10.2 EDN1 KNG1
10 ascending cholangitis 10.1 TGFB1 TNFRSF25
11 malignant essential hypertension 10.1 KNG1 TNFRSF25
12 renal hypertension 10.1 EDN1 KNG1
13 toxic diffuse goiter 10.0 TNFRSF10B TNFRSF25
14 nephrogenic systemic fibrosis 10.0 EDN1 TGFB1
15 impotence 10.0 EDN1 KNG1
16 idiopathic interstitial pneumonia 10.0 EDN1 TGFB1
17 phototoxic dermatitis 9.9 KNG1 TRIM21
18 lupus erythematosus 9.9
19 gingival fibromatosis 9.9 EDN1 TGFB1
20 crest syndrome 9.8
21 esophagitis 9.8
22 adie pupil 9.8 TNFRSF25 TRIM21
23 heart block, congenital 9.8 TNFRSF25 TRIM21
24 diffuse infiltrative lymphocytosis syndrome 9.8 TNFRSF10B TRIM21
25 systemic lupus erythematosus 9.7
26 skin disease 9.7
27 interstitial lung disease 9.7
28 lung disease 9.7
29 punctate epithelial keratoconjunctivitis 9.7 TNFRSF25 TRIM21
30 ovarian cancer 9.6
31 pneumothorax, primary spontaneous 9.6
32 rheumatoid arthritis 9.6
33 aplastic anemia 9.6
34 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.6
35 polyarteritis nodosa, childhood-onset 9.6
36 pulmonary hypertension 9.6
37 arthritis 9.6
38 crohn's disease 9.6
39 dermatomyositis 9.6
40 thrombotic thrombocytopenic purpura 9.6
41 pneumothorax 9.6
42 squamous cell carcinoma 9.6
43 purpura 9.6
44 kidney disease 9.6
45 bilateral breast cancer 9.6
46 subcorneal pustular dermatosis 9.6
47 polyarteritis nodosa 9.6
48 autonomic dysfunction 9.6
49 hypersensitivity reaction disease 9.4 TNFRSF25 TRIM21

Graphical network of the top 20 diseases related to Diffuse Scleroderma:



Diseases related to Diffuse Scleroderma
Sources

Symptoms & Phenotypes for Diffuse Scleroderma

About this section

UMLS symptoms related to Diffuse Scleroderma:


hidebound skin, pruritus, exanthema
Sources

Drugs & Therapeutics for Diffuse Scleroderma

About this section

Drugs for Diffuse Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147536-97-8 104865
2
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
3
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2 171596-29-5 110635
4
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
5
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 77-92-9 311
6 Vaccines Phase 4
7 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Endothelin Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
9 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
10 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
11 Vasodilator Agents Phase 4,Phase 2,Phase 3,Early Phase 1
12 Autonomic Agents Phase 4,Phase 2,Phase 3,Early Phase 1
13 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Platelet Aggregation Inhibitors Phase 4,Phase 2,Phase 3
16 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
17 Respiratory System Agents Phase 4,Phase 2,Phase 3
18 Sildenafil Citrate Phase 4,Phase 3,Phase 2,Early Phase 1 171599-83-0
19 Anti-Asthmatic Agents Phase 4
20 Bronchodilator Agents Phase 4
21 Fibrinolytic Agents Phase 4,Phase 2,Phase 3
22 Phosphodiesterase 3 Inhibitors Phase 4
23 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1
24 Acidophilus Nutraceutical Phase 4,Phase 3
25 Omega 3 Fatty Acid Nutraceutical Phase 4
26
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
27
Iloprost Approved, Investigational Phase 2, Phase 3 78919-13-8 6443959
28
Nitroglycerin Approved, Investigational Phase 3,Phase 2 55-63-0 4510
29
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Early Phase 1 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Early Phase 1 50-24-8 5755
31
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
32
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
33
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
34
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
35
Methocarbamol Approved, Vet_approved Phase 3,Phase 2 532-03-6 4107
36
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
37
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
38
Macitentan Approved Phase 3 441798-33-0
39
Alginic acid Approved, Experimental, Investigational Phase 3 9005-32-7
40
Domperidone Approved, Investigational, Vet_approved Phase 3 57808-66-9 3151
41
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
42
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
43
Acetylcholine Approved Phase 3,Phase 2 51-84-3 187
44
Mesna Approved, Investigational Phase 2, Phase 3, Phase 1 3375-50-6 598
45
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
46
Pirfenidone Approved, Investigational Phase 2, Phase 3,Phase 1 53179-13-8 40632
47
Fludarabine Approved Phase 3,Phase 1,Phase 2 21679-14-1, 75607-67-9 30751
48
Vidarabine Approved, Investigational Phase 3,Phase 1,Phase 2 24356-66-9 21704 32326
49
Lactulose Approved Phase 3 4618-18-2 11333
50
Prednisone Approved, Vet_approved Phase 3,Phase 1 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 350)

# Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Unknown status NCT02480335 Phase 4 bosentan
3 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Unknown status NCT01051960 Phase 4 Ambrisentan
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Bosentan in Systemic Sclerosis Completed NCT01395732 Phase 4 Bosentan
6 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Completed NCT01042158 Phase 4 tadalafil and ambrisentan upfront combination therapy
7 Pulmonary Artery Remodelling With Bosentan Completed NCT00595049 Phase 4 bosentan
8 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
9 Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases Recruiting NCT03388255 Phase 4 Polydeoxyribonucleotides
10 To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis Recruiting NCT03053739 Phase 4 Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo
11 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
12 Comparison of Esophageal and Anorectal Manometry Catheters Terminated NCT00204763 Phase 4
13 Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis Withdrawn NCT01497743 Phase 4 Lactobacillus
14 Intraoperative ICG for Systemic Sclerosis Withdrawn NCT03155464 Phase 4 Indocyanine Green
15 Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis Unknown status NCT02302352 Phase 3
16 High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis Unknown status NCT00428883 Phase 2, Phase 3 N-acetylcysteine (NAC)
17 Serial Night Time Position Splint on Systemic Sclerosis Unknown status NCT01586663 Phase 3 Drug treatment
18 Platelet Gel in Systemic Sclerosis Unknown status NCT00463125 Phase 2, Phase 3 Platelet Gel
19 Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases Unknown status NCT01387035 Phase 3
20 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
21 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
22 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
23 Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma Completed NCT00704665 Phase 3 Relaxin;Relaxin
24 Rituximab in Systemic Sclerosis Completed NCT01748084 Phase 2, Phase 3 Rituximab;Placebo (NaCl)
25 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
26 Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis Completed NCT00348296 Phase 3 High-dose intravenous immunoglobulin (Venoglobulin-IH)
27 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
28 Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients Completed NCT01474109 Phase 3 macitentan 3mg;macitentan 10mg;placebo
29 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3 Alginic acid;placebo (for domperidone);Domperidone;placebo (of alginic acid)
30 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
31 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
32 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
33 Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma Completed NCT00077584 Phase 3 Bosentan 62.5 mg;Bosentan 125 mg;Placebo
34 Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension Completed NCT00984932 Phase 3 Rosuvastatin
35 Scleroderma Lung Disease Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
36 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
37 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
38 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
39 Bosentan in Digital Ulcers Completed NCT00319696 Phase 3 bosentan
40 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Completed NCT01532869 Phase 3 Placebo;tocilizumab [RoActemra/Actemra];tocilizumab [RoActemra/Actemra]
41 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
42 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
43 Open-label Study With Bosentan in Interstitial Lung Disease Completed NCT00319033 Phase 2, Phase 3 bosentan
44 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3 Imiquimod 5% cream
45 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
46 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
47 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
48 Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
49 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
50 "As Required" Oral Sildenafil in Raynaud's Phenomenon Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo

Search NIH Clinical Center for Diffuse Scleroderma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: scleroderma, diffuse

Sources

Genetic Tests for Diffuse Scleroderma

About this section
Sources

Anatomical Context for Diffuse Scleroderma

About this section

MalaCards organs/tissues related to Diffuse Scleroderma:

38
Lung, Skin, Endothelial, Heart, Eye, Bone, T Cells
Sources

Publications for Diffuse Scleroderma

About this section

Articles related to Diffuse Scleroderma:

(show top 50) (show all 81)
# Title Authors Year
1
Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease. ( 28337853 )
2017
2
Predicting improvement in diffuse scleroderma: lessons learnt. ( 27221693 )
2016
3
Splenic Pseudoaneursym as the Cause of Recurrent Gastrointestinal Bleeding in a Woman With Diffuse Scleroderma. ( 26157926 )
2015
4
Subcutaneous calcifications in a patient with diffuse scleroderma. ( 23910621 )
2013
5
Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. ( 20058013 )
2012
6
Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. ( 20679474 )
2011
7
Reversible posterior leukoencephalopathy in diffuse scleroderma. ( 20576217 )
2010
8
A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. ( 19812599 )
2010
9
Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil. ( 19208586 )
2009
10
Subcorneal pustular dermatosis in a patient with rheumatoid arthritis and diffuse scleroderma. ( 19379649 )
2009
11
Autologous stem cell transplantation in diffuse scleroderma: impact on hand structure and function. ( 18336540 )
2008
12
Current approaches to the management of early active diffuse scleroderma skin disease. ( 18329538 )
2008
13
High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. ( 17381465 )
2007
14
Kidney disease other than renal crisis in patients with diffuse scleroderma. ( 15801020 )
2005
15
A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. ( 15769789 )
2005
16
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. ( 14679295 )
2004
17
Bilateral breast cancer associated with diffuse scleroderma. ( 14659331 )
2003
18
Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. ( 12605319 )
2003
19
Methotrexate for the treatment of early diffuse scleroderma: comment on the article by Pope et al. ( 11920427 )
2002
20
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. ( 11157146 )
2001
21
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. ( 11407694 )
2001
22
Pseudohypertension in a patient with diffuse scleroderma. ( 11273902 )
2001
23
Unusual overlap of systemic lupus erythematosus and diffuse scleroderma. ( 11247318 )
2001
24
Severe organ involvement in systemic sclerosis with diffuse scleroderma. ( 11083266 )
2000
25
Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. ( 10943881 )
2000
26
Minocycline in early diffuse scleroderma. ( 9848358 )
1998
27
Prevalence of pulmonary hypertension in limited and diffuse scleroderma. ( 8989070 )
1996
28
Thrombotic thrombocytopenic purpura in a patient with diffuse scleroderma. ( 9251403 )
1996
29
Seizures in a patient with diffuse scleroderma. ( 7494776 )
1995
30
Interstitial Lung Disease Developing during Treatment with Cyclosporine in a patient with Diffuse Scleroderma, Aplastic Anemia and Crohn's Disease: Implications for Pathogenesis and Treatment. ( 19077999 )
1995
31
Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma. ( 8151564 )
1994
32
Autonomic dysfunction in diffuse scleroderma vs CREST: an assessment by computerized heart rate variability. ( 7837149 )
1994
33
A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. ( 2003858 )
1991
34
Progressive systemic sclerosis (diffuse scleroderma) and radiotherapy. ( 2242481 )
1990
35
Ketotifen-induced remission in progressive early diffuse scleroderma: evidence for the role of mast cells in disease pathogenesis. ( 2393046 )
1990
36
Clinical association of autoantibodies to fibrillarin with diffuse scleroderma and disseminated telangiectasia. ( 2254467 )
1990
37
Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. ( 2787182 )
1989
38
Mast cell numbers in diffuse scleroderma. ( 3813593 )
1987
39
Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. ( 3490227 )
1986
40
Scl-86, a marker antigen for diffuse scleroderma. ( 3980727 )
1985
41
Landmark article May 23, 1942: Diffuse collagen disease. Acute disseminated lupus erythematosus and diffuse scleroderma. By Paul Klemperer, Abou D. Pollack and George Baehr. ( 6366270 )
1984
42
Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. ( 6690931 )
1984
43
Myocardial function and perfusion in the CREST syndrome variant of progressive systemic sclerosis. Exercise radionuclide evaluation and comparison with diffuse scleroderma. ( 6475990 )
1984
44
Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. ( 6628005 )
1983
45
Acute diffuse scleroderma. ( 6165202 )
1981
46
Reversible acute renal faiure in diffuse scleroderma. ( 7408249 )
1980
47
Progressive systemic sclerosis (diffuse scleroderma). A follow-up report of treatment with potaba. ( 4576830 )
1973
48
Esophageal reconstruction for stenosis due to diffuse scleroderma. Utilizing blunt dissection of esophagus. ( 4783042 )
1973
49
Chromosomal breakage in diffuse scleroderma. A study of 27 patients. ( 5125548 )
1971
50
Epidemiology of fatal systemic sclerosis (diffuse scleroderma). A 15-year survey in Baltimore. ( 6025228 )
1967
Sources

Variations for Diffuse Scleroderma

About this section
Sources

Expression for Diffuse Scleroderma

About this section
Search GEO for disease gene expression data for Diffuse Scleroderma.
Sources

Pathways for Diffuse Scleroderma

About this section

Pathways related to Diffuse Scleroderma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
11.85 MNDA TNFRSF10B TNFRSF25
2
Apoptosis and Autophagy 4
11.07 MNDA TNFRSF10B TNFRSF25
3
Lung fibrosis 1
11.06 EDN1 TGFB1
4
Syndecan-2-mediated signaling events 1
10.47 KNG1 TGFB1
Sources

GO Terms for Diffuse Scleroderma

About this section

Cellular components related to Diffuse Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 KNG1 TGFB1

Biological processes related to Diffuse Scleroderma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.72 KNG1 MNDA TGFB1
2 response to drug GO:0042493 9.69 EDN1 TGFB1 TOP1
3 regulation of apoptotic process GO:0042981 9.67 TGFB1 TNFRSF10B TNFRSF25
4 cell surface receptor signaling pathway GO:0007166 9.63 EDN1 TNFRSF10B TNFRSF25
5 regulation of cell proliferation GO:0042127 9.61 TGFB1 TNFRSF10B TNFRSF25
6 response to lipopolysaccharide GO:0032496 9.58 EDN1 TNFRSF10B TNFRSF25
7 positive regulation of MAP kinase activity GO:0043406 9.54 EDN1 TGFB1
8 cellular response to transforming growth factor beta stimulus GO:0071560 9.52 EDN1 TGFB1
9 protein destabilization GO:0031648 9.48 PYHIN1 TRIM21
10 inflammatory response GO:0006954 9.46 KNG1 TGFB1 TNFRSF10B TNFRSF25
11 positive regulation of protein localization to nucleus GO:1900182 9.37 PYHIN1 TGFB1
12 regulation of blood vessel size GO:0050880 9.32 EDN1 KNG1
13 negative regulation of blood coagulation GO:0030195 9.26 EDN1 KNG1
14 response to salt GO:1902074 8.96 EDN1 TGFB1
15 positive regulation of odontogenesis GO:0042482 8.62 EDN1 TGFB1

Molecular functions related to Diffuse Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor-activated receptor activity GO:0005031 8.62 TNFRSF10B TNFRSF25
Sources

Sources for Diffuse Scleroderma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....